Scleral Contact Lens Insertion Solution Study

Irregular; Contour of Cornea Clinical Trial

Official title:

Scleral Contact Lens Insertion Solution Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03612284
• Other study ID #: 2017H0141
• Status: Completed
• Phase: N/A
• Start date: November 27, 2017
• Est. completion date: November 30, 2018

Study information

• Verified date: January 2019
• Source: Ohio State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the clinical ocular compatibility (feasibility of safety and efficacy) of a patented solution (US Patent 2,259,437, Stone) which contains multiple essential ions and has a pH and tonicity which more closely mimics human tears as compared to the subjects' current habitual scleral lens insertion solution.

Description:

The sterile solution is provided by prescription for each patient by a local compounding pharmacy in unit dose containers. The initial exposure - filling the posterior bowl of the scleral contact lens by the Investigator and applying the lens to the eye - will be monitored in the office for one hour, prior to any dispensing of the solution to the patient for their use at home or work.

This is a one week, unmasked comparison of the new solution to the subject's habitual solution used for scleral lens insertion. The (historical) control is the saline habitually used by the subjects.

The sample size is determined to be manageable to insure close supervision of the subjects in these initial trials and to inform us for future safety and efficacy trials.

The primary safety outcome measure will be slit lamp examination of the ocular anterior segment and the secondary outcome measure will be photo-documentation by ocular coherence tomography of the clouding of the tears between the cornea and scleral contact lens. The primary efficacy outcome will be ocular comfort as assessed by questionnaire.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 30, 2018
• Est. primary completion date: November 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years and older.

• Wear a scleral contact lens habitually 6 or more hours a day.

• Needs to remove scleral lens due to fogging and refill or definitely reports fogging.

• Must have worn habitual scleral lens for at least 3 months

• Willing and able to attend study visits.

Exclusion Criteria:

• Currently under treatment for an eye infection or inflammation such as adapted keratoconus or healed post penetrating keratoplasty. Stable keratoconus is acceptable.

• Currently taking topical ophthalmic prescription medications.

• Current medical eye complications such as glaucoma or uveitis.

• Recent corneal surgery

• Sjogrens or other clinically significant active ocular surface disease.

Related Conditions & MeSH terms

• Irregular; Contour of Cornea

Intervention

Device:
• contact lens insertion solution
This contact lens solution is being tested for safety and comfort and is not an "intervention." Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire.

Locations

Country	Name	City	State
United States	The Ohio State University College of Optometry	Columbus	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Jennifer Fogt	Contamac Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in corneal staining or corneal disruption as assessed with clinical biomicroscope	ocular safety examination	immediately after first use of solution and again in 5 to 9 days
Primary	Comfort and vision quality as assessed by Ocular Surface Disease Index (OSDI) questionnaire	Subjects will answer the OSDI questionnairre (score of 0-48) used to assess symptoms related to comfort and vision. The survey will be done with the subjects regular solution and repeated after using the test solution	5 to 9 days
Primary	Comfort as assessed by Current Symptoms Survey (CSS)	Subjects will respond to the CSS survey (scores of 0-100 for various symptoms) - used to assess symptoms related to comfort and vision. The survey will be done with the subjects regular solution and repeated after using the test solution	5 to 9 days